Venus launches its patented research product ACHNIL in India
Venus Remedies Ltd has informed BSE regarding a Press Release dated July 11, 2011 titled "Venus launches its patented research product ACHNIL in India".Press Release:"The Company has launched a novel formulation ACHNIL brand of Aceclofenac- injection in India. ACHNIL" injection is a single Shot.., last day long" formulation.... Venus Remedies' "ACHNIL", once-a-day painkiller, gets EU Patent
Venus Remedies Ltd has informed BSE regarding "Venus Remedies' "ACHNIL", once-a-day painkiller, gets EU Patent""The Company has been granted patent by European Patent Office (EPO) for its research drug "ACHNIL" , a once-a-day painkiller injection. This patent grant will be in force till 2025 in the member countries of EPO which will further reinforce the market position of Venus Remedies in the major economies such as Germany, UK, France,... Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011
Venus Remedies Ltd has informed BSE that Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011.Announcement :"The Company has been awarded Gold Medal in DST-Lockheed Martin India Innovation Growth Program - 2011, for one of its Integrated Medicinal research product TROIS. The program is conducted in association with Department of Science and Technology. Govt. of India, Lockheed... Appointment of Compliance Officer
Venus Remedies Ltd has informed BSE that Ms. Neha Kodan, Company Secretary has been appointed as Compliance Officer w.e.f. April 11, 2011 as Ms. Nidhi Singla, Company Secretary has resigned from the Company. Financial Results for Mar 31, 2011
Venus Remedies Ltd has informed BSE about the Financial Results for the period ended March 31, 2011. Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule
Venus Remedies Ltd has informed BSE that "Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". (For more details kindly refer Corporate Announcements on www.bseindia.com). Venus Remedies Limited wins QC-100 TQM (Total Quality Management) Award in Gold Category from Geneva
Venus Remedies Ltd has informed BSE that Venus Remedies Limited wins QC-100 TQM (Total Quality Management) Award in Gold Category from Geneva.Announcement:"Company bagged a prestigious international award QC-100 TQM (Total Quality Management) in Gold Category in recognition of commitment to Quality, System efficiency, Leadership, Technology and Innovation. The awards were given by Business Initiative Directions (BID) International... Outcome of Board Meeting
Venus Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 30, 2011, have approved allotment of 6,00,000 equity shares of Rs. 10 each to promoter group Company pursuant to conversion of warrants fully convertible into equity shares. Board Meeting on Mar 30, 2011
Venus Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on March 30, 2011, inter alia, to consider and approve allotment of 6,00,000 equity shares of Rs. 10 each to promoter group Company pursuant to conversion of warrants fully convertible into equity shares.